GENOMICS OF PANCREATIC TUMOURS
|
|
- Poppy Barrett
- 5 years ago
- Views:
Transcription
1 GENOMICS OF PANCREATIC TUMOURS - WHAT WE NOW KNOW Ann-Marie Patch, 1 Andrew Barbour, 2,3 Nicola Waddell 1,4 1. QIMR Berghofer Medical Research Institute, Herston, Brisbane, Queensland, Australia. 2. Surgical Oncology Group, School of Medicine, The University of Queensland, Translational Research Institute at the Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia. 3. Department of Surgery, School of Medicine, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia. 4. Institute for Molecular Bioscience, The University of Queensland, St Lucia, Brisbane, Queensland, Australia. nic.waddell@qimrberghofer.edu.au Abstract Each year, over 2500 patients in Australia are diagnosed with pancreatic cancer. Pancreatic cancer is one of the most lethal tumour types with a five year survival of just 5%, thus there is a need to find alternative approaches to treatment. In recent years, the application of next generation sequencing has revealed the complex genomic landscape of pancreatic cancer, uncovering the mutation processes that occur during tumour development and has begun to identify new or repurposed therapeutic opportunities for pancreatic cancer patients. The identification of targets for therapy is a crucial goal of the large next generation sequencing studies as we move into an era of targeted or personalised medicine, where drugs will be selected based on the characteristics of a patient s tumour. Due to the large degree of heterogeneity in pancreatic cancer, a personalised approach to treatment seems particularly warranted. This review will summarise some of the key findings from genome sequencing of pancreatic cancer, describing the major driver genes and perturbed pathways, and highlighting some of the new potential and promising therapeutic opportunities that have been uncovered. Cancer is a genetic disease caused by mutations that accumulate within the DNA sequence of cells. Cells that are normally functioning have repair mechanisms that detect and repair DNA mutations. If however, mutations occur in key regions within the genome, they can disrupt the failsafe repair and checkpoint regulatory system and may enable the mutated cells to grow uncontrollably, resulting in cancer. Mutations affecting genes that confer regulatory or growth advantages are positively selected in tissues to promote tumorigenesis and are referred as driver mutations. 1 The dysregulated cellular system also permits other mutations that do not contribute to tumorigenesis to escape repair. These are referred to as passenger mutations as they are carried along in the clonal expansion of cancer cells. In recent years, next generation sequencing has made it feasible to generate genome wide catalogues of the DNA mutations present in individual cancers. Two large sequencing initiatives were established to use this technology to sequence thousands of tumour samples from many different cancer types - The Caner Genome Atlas ( and the International Cancer Genome Consortium ( 2 The main goals of these consortia include cataloguing of commonly mutated genes and disrupted cellular mechanisms that might be drivers of cancer, and identification of actionable markers for therapy in the hope of improving therapy selection and patient outcome. Such genomic studies have revealed the molecular basis underlying pancreatic cancer, identified molecular subtypes and discovered potential therapeutic opportunity in repurposing treatments. Need for molecular profiling of pancreatic cancer The term pancreatic cancer describes several tumour types histologically classified on the tissue structures from which they arise. Individual or up to hundreds of samples from the most common pancreatic tumour types have been subjected to exome or whole genome sequencing, however there remain rare subtypes for which no genomic data has been generated. For the tumour types with genomic data, the studies have confirmed and identified key driver genes which are frequently mutated within each tumour subgroup (table 1). The genomic findings have reinforced that pancreatic cancer is a heterogeneous disease comprised of many distinct tumour subgroups. 3 In addition, the degree of heterogeneity between tumours from the same tumour subgroup is high, as tumours of the same subgroup may harbour a different repertoire of 6
2 mutations and few genes are mutated at high frequency within sample cohorts. Instead, many recurrently mutated genes are present only at low frequency. 4 This large number of genes mutated at a low frequency impacts on the ability to robustly identify driver mutations, genes or pathway events. One solution is to increase the number of samples studied to increase the power of detection, however this may also increase the confounding passenger mutation signal. Another is that improvements are being made to next generation sequencing analysis methods which enable integrated multiple data types to pinpoint key tumour promoting pathways. to survey the complete repertoire of somatic mutations in PDAC. 7 To optimally determine the drivers of PDAC, a recent meta-analysis of available genome data was conducted (Bailey et al, in press Nature). Together, these studies have iteratively identified the genes and pathways which are recurrently mutated in PDAC. Frequent somatically mutated genes There are four genes which are frequently mutated in PDAC (mutated in >30% of samples), and many more genes which are less frequently seen but still significantly mutated (mutated at a higher frequency than by chance Table 1: Frequently mutated genes in pancreatic cancer tumour subgroups detected by sequencing. Pancreatic tumour type Driver gene Approximate proportion of mutated samples Reference KRAS > Ductal adenocarcinoma TP53 SMAD ,7 5,7,8 CDKN2A ,7,8 Intraductal papillary-mucinous neoplasm (IPMN) KRAS GNAS ,10 Acinar cell carcinoma TP MEN1 44 Pancreatic neuroendocrine tumours DAXX/ATRX 43 MTOR pathway genes 15 Genome studies Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent tumour type which accounts for approximately 90% of all pancreatic tumours, 13 and has been the most comprehensively studied by genome sequencing. Genome studies were initially performed by amplicon exon sequencing of small numbers of PDAC cell lines and patient derived xenograft mouse models (n=24), 5 or cell lines (n=15). 4 Subsequently, exome sequencing was performed on large cohorts of patient tumour samples (n=99), 6 and micro-dissected tumours (n=109). 8 These exome studies identified point mutations and small indels, but had limited ability to detect chromosome structural rearrangement, an alternative mechanism of gene mutation which can result in inactivation of tumour suppressors by gene breakage or activation of oncogenes by amplification of dysregulation. The genome wide view of large rearrangements can be detected by whole genome sequencing, therefore the International Cancer Genome Consortium pancreatic project recently employed whole genome sequencing alone) which affect common pathways and thus are likely to be driving the disease (figure 1). The most frequently mutated gene is the KRAS oncogene. The KRAS protein is involved in RAS signalling and cellular growth through the MAPK and PIK3CA pathways and is mutated in >90% of PDAC cases. 4-7 Mutations in the KRAS gene are clustered in hotspots and result in activation changes at codon (92 % of KRAS mutated cases) and less frequently at codon 13 and 61 (~8 % of KRAS mutated cases). 5-8 The type of KRAS mutation may have clinical significance, as patients with codon 61 mutations have been shown to have a more favourable outcome to patients with other KRAS mutations. 8 The remaining three genes mutated at a high frequency are tumour suppressor genes and frequently harbour mutations combined with a loss of heterozygosity in PDAC. TP53 is an important regulator of cell response to DNA damage and is mutated in >70% of patients. CDKN2A is a cell cycle regulation gene and SMAD4 is involved in TGF-β signalling. Both are mutated in >30% of samples
3 Figure 1: Frequently mutated pathways in PDAC. A summary of the pathways and genes which are mutated in PDAC are shown: a) The proportion of PDAC samples which contain mutations in each pathway is represented by the circular histogram; b) A selection of the genes which have been reported in each pathway are shown. In addition to these four key driver genes, there are many genes mutated at low frequency which are also likely drivers of disease. These include the ARID1A gene, which is involved in chromatin modelling and was identified as recurrently mutated in different samples, and detected in multiple studies. 5-8 Other genes have also been detected by more than one study including TGFRB2, 4-6 MLL3 and SF3B 1,5,6 and ROBO 2,6,7 while many more genes have been identified as significantly mutated in a small percentage of samples. This so called long tail of uncommon, but recurrently mutated genes, highlights the between patient tumour heterogeneity and indicates that more samples will need to be characterised to identify all drivers of pancreatic cancer. Frequently perturbed pathways The large numbers of genes that are recurrently mutated suggest that PDACs are highly heterogeneous with multiple pathways affected by mutation. The first study which systematically sequenced the exons of thousands of genes in pancreatic cancer described core signalling pathways as driving PDAC, 5 and included pathways whose dysregulation has been described as a hallmark of many other cancer types. 14,15 The PDAC core signalling pathways have subsequently been refined as more genome data has been generated. The axon guidance pathway, particularly SLIT/ROBO signalling, was later identified as frequently mutated, 6 and subsequently shown to be frequently methylated in PDAC. 16 The chromatin modelling SWI/SNF pathway was also identified in 42% of cases and frequently involves mutations in ARID1A which occur in 15% of cases and has been associated with a poor outcome. 8 A summary of the genes and pathways perturbed in PDAC is shown in figure 1. Mutational signatures Cancer genomes may carry tens to thousands of somatic mutations. A handful of these mutations will have a functional consequence and act as drivers of disease, while the vast majority are passenger or bystander mutations which have little functional consequence. However, all the mutations (driver and passenger) can reveal information about the aetiology of each tumour. Genomic mutations range from single base substitutions to large chromosomal structural rearrangements and the pattern or distribution of these mutations can reveal important insights into how the tumours arose. In particular, the sequence context of single base substitutions can be used to identify the underlying mutational processes or signatures which have occurred in tumour development. 17,18 For many signatures the cause is unknown, while others are associated with mutagenic exposure e.g. tobacco smoking, ultra-violet light and defective DNA damage repair. 17,18 In PDAC, at least six mutation signatures have been described (see signatures). These include two signatures that are present in most PDACs and are ubiquitously expressed in many other tumour types, one of which is associated with ageing or deamination of 5-methylcytosine, while the cause of the other signature is not known. Other mutation signatures detected include two signatures thought to be caused by the AID/APOBEC family, however 8
4 the precise mechanism resulting in the AID/APOBEC signature in PDAC is not known. The remaining two signatures are linked with defects in DNA damage repair. The first is termed the BRCA signature, and is associated with a defective homologous recombination DNA repair pathway. 7,19,20 Tumours which contain a high proportion of mutations classified within the profile of the BRCA signature are present in approximately 14% of PDAC samples. These tumours are also associated with unstable tumour genomes which contain a high number of rearrangements. 7 In PDAC, many of the tumours with a high proportion of BRCA signature mutations contain pathogenic germline variants or somatic mutations in key genes involved in homologous recombination, including BRCA1, BRCA2, ATM and PALB2. 7 However, for some BRCA signature high tumours, the genes or processes driving this signature have yet to be identified. The second DNA damage repair signature correlates with a mismatch repair (MMR) deficiency and has been identified in microsatellite unstable tumours which are associated with a hypermutation phenotype. 17 Microsatellite instability and the underlying MMR defects have been shown to occur occasionally in PDAC (<10% cases), 21 and PDAC tumours with a high mutation rate have been associated with loss of the mismatch repair gene MLH1. 4 However, to better understand the prevalence of MMR in PDAC and determine what is driving the MMR signature, a systematic screen of a large cohort of PDAC is required. Patterns of rearrangements reveal genomic subtypes The patterns of large chromosomal rearrangements have been used to classify PDAC into four molecular subtypes, 7 which are termed as stable, scattered, locally rearranged and unstable. Similar groups have also been described in other tumour types, including oesophageal and ovarian cancer. 20,22 The stable subtype contains few genomic rearrangements and comprises 20% of PDAC samples. The scattered subtype contains a modest number of chromosome rearrangements distributed throughout the genome and comprises 36% of samples. In contrast, the locally rearranged PDACs contain focal clusters of breakpoints on one or few chromosomes resulting in amplification of several oncogenes (30% of samples). The genomic location of the focal amplifications affects a variety of candidate PDAC oncogenes, each amplified in a small subset of patients, suggesting that the locally rearranged PDACs are promiscuous in their selection of oncogenes. The candidate oncogenes include the ERBB2 gene which encodes the HER2 oncoprotein, FGFR1, MET, CDK6, PIK3R3 and PIK3CA. The unstable subtype contains many structural rearrangements (>200) distributed throughout the genome. 7 The unstable genomes are associated with a high number of mutations contributing to the BRCA signature and frequently contain mutations or pathogenic germline variants in genes involved in homologous recombination. Opportunity for targeted treatment PDAC is an aggressive disease with a five year survival of 5%. The majority of PDAC patients with advanced disease will receive gemcitabine based chemotherapies which is the standard of care, but this only provides a marginal survival advantage. Thus there remains a pressing need to improve therapy regimes. Personalised or targeted treatment, whereby drugs will be selected based on the characteristics of the tumour will become more prevalent. The large degree of heterogeneity in PDAC means it is an ideal disease for a personalised approach. In support of this there have been several reviews discussing some of the therapeutic opportunities in PDAC and a phase II trial (IMPaCT) was established to implement and test the value of precision medicine for recurrent or metastatic pancreas cancer Targeting the DNA repair pathway The large amount of PDAC mutation data has revealed an abundance of therapeutic opportunity. Of particular note is the potential to target defects in DNA damage repair pathways. Individual case reports of patients with advanced gemcitabine resistant disease that harbour defects in the homologous recombination pathway are showing positive responses to DNA damaging agents. 7,27 Genome studies revealed that tumours with defective homologous recombination can be associated with a BRCA signature mutational profile and unstable rearrangement patterns, and comprise 14% of PDAC samples. 7 Prospective patient clinical data and preclinical mouse models have demonstrated the potential utility of targeting these tumours with platinum based therapy. A challenge now is to identify those tumours with defective homologous recombination, so there is need for a test, other than whole genome sequencing, which has clinical utility to accurately and rapidly identify tumours that have a defective homologous recombination pathway. Defects in an alternative DNA repair pathway, MMR, occur in small number of PDAC tumours. Similar to other cancer types such as colorectal, 28 these tumours are associated with hypermutation. Due to the evidence suggesting that a high mutation burden may predict the likely chance of success of cancer immunotherapies, 29 further work is warranted to determine whether this group of MMR defective PDAC tumours will respond to immunotherapies. Other candidate targets for therapy Oncogenic driver mutations are major treatment targets for molecular cancer therapies. There are several genes which are amplified at low frequency in PDAC (<5%) for which there are inhibitors developed for different tumours, including HER2, CDK4/6, FGFR and PI3-kinases, which have the potential to be utilised in PDAC treatment. HER2 amplification is one of the best characterised and occurs in 20% of breast cancers. Targeting this event with the anti-her2 monoclonal antibody trastuzumab has revolutionised the outcome of patients with HER2 positive aggressive breast cancer. 30,31 HER2 amplification has been detected in other tumours types including oesophageal, lung, bladder and gastric cancer, raising the possibility that anti-her2 therapy can be repurposed to other tumour types. Encouragingly, in gastric cancer it has 9
5 been shown that HER2-overexpressing tumours treated with trastuzumab gain a survival advantage. 32 In PDAC, amplifications of HER2 occur in 2% of cases, which makes it an attractive target for therapy. 33 Pathways which are perturbed in PDAC can also be targeted therapeutically, although identification of these pathways in each tumour can be problematic. The genome sequencing studies have been immensely useful and have identified the genes which are significantly mutated in these pathways, which may represent markers of therapy response. For example, a small proportion of PDAC samples contain mutations in RNF43, which is involved in Wnt signalling. The presence of RNF43 mutation has been shown to act as a predictive biomarker for Wnt inhibitors in PDAC cell lines. 34 In addition, other candidate therapeutic targets which are mutated in small sets of PDAC include mutations in the splicing factor SF3B1, as SF3B1 mutant breast cancer cells are sensitive to a SF3b complex inhibitor spliceostatin A. 35 These and other candidate targets now need to be verified experimentally for efficacy to determine if they can be used in treatment of PDAC. Conclusion There has been enormous progress in our understanding of the genes and pathways mutated in pancreatic cancer. These findings have informed about the mutational processes during tumour development and revealed new therapeutic opportunities. Pancreatic cancer is a heterogeneous disease and so it makes sense that this disease will benefit from a personalised approach to patient treatment. Although not specific to pancreatic cancer, a number of challenges remain for targeted therapy. These include development of suitable biomarkers of therapy selection, the within tumour heterogeneity which means some cells will contain the targeted mutation but other cells may not, and the potential of drug resistance development. However, in the near future it is anticipated that large collaborative clinical trials using many of the markers identified by genome sequencing, will commence in the treatment of PDAC. References 1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458: Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature. 2010;464: Cowley MJ, Chang DK, Pajic M, et al. Understanding pancreatic cancer genomes. Journal of hepato-biliary-pancreatic sciences. 2013;20: Wang L, Tsutsumi S, Kawaguchi T, et al. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome research. 20;22: Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321: Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 20;491: Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518: Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nature communications. 2015;6: Tan MC, Basturk O, Brannon AR, et al. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. Journal of the American College of Surgeons. 2015;220: e Furukawa T, Kuboki Y, Tanji E, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Scientific reports. 2011;1: La Rosa S, Bernasconi B, Frattini M, et al. TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. Virchows Archiv : an international journal of pathology Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mtor pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331: Moore PS, Beghelli S, Zamboni G, et al. Genetic abnormalities in pancreatic cancer. Molecular cancer. 2003;2: Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144: Nones K, Waddell N, Song S, et al. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. International journal of cancer. Journal international du cancer. 2014;135: Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500: Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Current opinion in genetics & development. 2014;24: Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 20;149: Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521: Yamamoto H, Itoh F, Nakamura H, et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer research. 2001;61: Nones K, Waddell N, Wayte N, et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nature communications. 2014;5: Chantrill LA, Nagrial AM, Watson C, et al. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21: Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug design, development and therapy. 2015;9: Frank TS, Sun X, Zhang Y, et al. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Cancer letters. 2015;363: Seicean A, Petrusel L, Seicean R. New targeted therapies in pancreatic cancer. World journal of gastroenterology. 2015;21: Villarroel MC, Rajeshkumar NV, Garrido-Laguna I et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Molecular cancer therapeutics. 2011;10: National Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 20;487: Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348: Elster N, Collins DM, Toomey S, et al. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. Breast cancer research and treatment. 2015;149: Guarneri V, Frassoldati A, Bottini A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20;30: Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376: Chou A, Waddell N, Cowley MJ, et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome medicine. 2013;5: Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2013;110: Maguire SL, Leonidou A, Wai P, et al. SF3B1 mutations constitute a novel therapeutic target in breast cancer. The Journal of pathology 2015;235:
CANCER FORUM. March 2016 Volume 40 Number 1. FORUM: Pancreatic cancer. Tom Reeve Award for Outstanding Contribution to Cancer Care
CANCER FORUM March 2016 Volume 40 Number 1 FORUM: Pancreatic cancer Tom Reeve Award for Outstanding Contribution to Cancer Care Research on relocation for specialist treatment report cancerforum.org.au
More informationBiology of cancer development in the GI tract
1 Genesis and progression of GI cancer a genetic disease Colorectal cancer Fearon and Vogelstein proposed a genetic model to explain the stepwise formation of colorectal cancer (CRC) from normal colonic
More informationAccepted Manuscript. Pancreatic Cancer Subtypes: Beyond Lumping and Splitting. Andrew J. Aguirre
Accepted Manuscript Pancreatic Cancer Subtypes: Beyond Lumping and Splitting Andrew J. Aguirre PII: S0016-5085(18)35213-2 DOI: https://doi.org/10.1053/j.gastro.2018.11.004 Reference: YGAST 62235 To appear
More informationCancer Genomics. Nic Waddell. Winter School in Mathematical and Computational Biology. July th
Cancer Genomics Nic Waddell Winter School in Mathematical and Computational Biology 6th July 2015 Time Line of Key Events in Cancer Genomics Michael R. Stratton Science 2011;331:1553-1558 The Cancer Genome
More informationIntegration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium
Integration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium Ulrike Peters Fred Hutchinson Cancer Research Center University of Washington U01-CA137088-05, PI: Peters
More informationKeynote Lecture 1 Advances in Molecular Biology of Pancreatic Cancer: Understanding Genetic Complexity and Molecular Heterogeneity
Keynote Lecture 1 Advances in Molecular Biology of Pancreatic Cancer: Understanding Genetic Complexity and Molecular Heterogeneity Volker Ellenrieder, MD, PhD University Hospital Gӧttingen Gӧttingen, Germany
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationBiomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club
Biomarker development in the era of precision medicine Bei Li, 23.08.2016 Interdisciplinary Technical Journal Club The top ten highest-grossing drugs in the United States help between 1 in 25 and 1 in
More informationNext generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
More informationGenomic Instability. Kent Nastiuk, PhD Dept. Cancer Genetics Roswell Park Cancer Institute. RPN-530 Oncology for Scientist-I October 18, 2016
Genomic Instability Kent Nastiuk, PhD Dept. Cancer Genetics Roswell Park Cancer Institute RPN-530 Oncology for Scientist-I October 18, 2016 Previous lecturers supplying slides/notes/inspiration Daniel
More informationAdenocarcinoma of the pancreas
Adenocarcinoma of the pancreas SEMINARS IN DIAGNOSTIC PATHOLOGY 31 (2014) 443 451 Ralph H.Hruban, MD, David S. Klimstra, MD Paola Parente Anatomia Patologica Casa Sollievo della Sofferenza San Giovanni
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationClonal evolution of human cancers
Clonal evolution of human cancers -Pathology-based microdissection and genetic analysis precisely demonstrates molecular evolution of neoplastic clones- Hiroaki Fujii, MD Ageo Medical Laboratories, Yashio
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationIdentification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma Nathaniel L Jones 1, Joanne Xiu 2, Sandeep K. Reddy 2, Ana I. Tergas 1, William
More informationPancreatic intraepithelial
Pancreatic intraepithelial neoplasia (PanIN) Markéta Hermanová St. Anne s University Hospital Brno Faculty of Medicine, Masaryk University Precursor lesions of invasive pancreatic cancer Pancreatic intraepithelial
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationFuture Perspectives in mpca. Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France
Future Perspectives in mpca Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France Number of Novel Therapies and Targets in Pancreatic Cancer Are Expanding Garrido-Laguna I, et al. Nat Rev Clin Oncol.
More informationLiposarcoma*Genome*Project*
LiposarcomaGenomeProject July2015! Submittedby: JohnMullen,MD EdwinChoy,MD,PhD GregoryCote,MD,PhD G.PeturNielsen,MD BradBernstein,MD,PhD Liposarcoma Background Liposarcoma is the most common soft tissue
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationPrecision medicine: How to exploit the growing knowledge on the evolving genomes of cells to improve cancer prevention and therapy.
Precision medicine: How to exploit the growing knowledge on the evolving genomes of cells to improve cancer prevention and therapy Joe Costello, PhD Department of Neurological Surgery A more accurate and
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationProtein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies
Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Dr. Maricel G. Kann Assistant Professor Dept of Biological Sciences UMBC 2 The term protein domain
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationUnità Operativa di Oncologia Medica Direzione Scientifica Istituto Tumori Giovanni Paolo II Bari.
Unità Operativa di Oncologia Medica Direzione Scientifica Istituto Tumori Giovanni Paolo II Bari n.silvestris@oncologico.bari.it LAPACT mffox + PEGPH20 (SWOG study) COMPASS trial Immune landscape ABSTRACT
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationHER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD
HER-2/neu Analysis in Gastroesophageal and Gastric Adenocarcinoma Keith Daniel Bohman, MD Carcinoma of the stomach is the fourth most common cancer and second most frequent cause of cancer-related mortality
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationPancreatic Cytopathology: The Solid Neoplasms
Pancreatic Cytopathology: The Solid Neoplasms Syed Z. Ali, M.D. Professor of Pathology and Radiology Director of Cytopathology The Johns Hopkins Hospital Baltimore, Maryland Pancreatic Cytopathology: Past,
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationShould novel molecular therapies replace old knowledge of clinical tumor biology?
Should novel molecular therapies replace old knowledge of clinical tumor biology? Danai Daliani, M.D. Director, 1 st Oncology Clinic Euroclinic of Athens Cancer Treatments Localized disease Surgery XRT
More informationnumber Done by Corrected by Doctor Maha Shomaf
number 19 Done by Waseem Abo-Obeida Corrected by Abdullah Zreiqat Doctor Maha Shomaf Carcinogenesis: the molecular basis of cancer. Non-lethal genetic damage lies at the heart of carcinogenesis and leads
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationSecuenciación masiva: papel en la toma de decisiones
Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.
More informationPancreatic Adenocarcinoma: What`s hot
Pancreatic Adenocarcinoma: What`s hot Eva Karamitopoulou-Diamantis Institute of Pathology University of Bern 11.09.2018, 30th ECP, Bilbao Pancreatic Cancer and the Microbiome The Pancreatic Cancer Microbiome
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20
More informationCollaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationDr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS
Molecular Profiling of Cancer Cells Strategies for Developing Biomarkers for Targeted Therapies of Cancer Dr. Pravin D. Potdar. M.Sc, Ph.D, D.M.L.T.,DHE, DMS Head, Department of Molecular Medicine and
More informationEnterprise Interest Thermo Fisher Scientific / Employee
Enterprise Interest Thermo Fisher Scientific / Employee A next-generation sequencing assay to estimate tumor mutation load from FFPE research samples Fiona Hyland. Director of R&D, Bioinformatics Clinical
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 28
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationOsamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationASCO Poster Review PANCREATIC CANCER
ASCO Poster Review PANCREATIC CANCER Dr.ssa Michela Squadroni U.O. Oncologia Humanitas Gavazzeni Bergamo TOPICAL ISSUES Gemcitabine/Nab-paclitaxel and FOLFIRINOX comparison Neoadjuvant and perioperative
More informationThe lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):
DNA Sequencing Publications Standard Sequencing 1 Carro MS et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun;5(11) 2 Lassandro L et al. The DNA sequence
More informationPlasma-Seq conducted with blood from male individuals without cancer.
Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationMoving molecular subtypes to the clinic in gastric cancer
Editorial Moving molecular subtypes to the clinic in gastric cancer Joseph Chao 1, Jeeyun Lee 2, Samuel J. Klempner 3,4 1 Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More information609G: Concepts of Cancer Genetics and Treatments (3 credits)
Master of Chemical and Life Sciences Program College of Computer, Mathematical, and Natural Sciences 609G: Concepts of Cancer Genetics and Treatments (3 credits) Text books: Principles of Cancer Genetics,
More informationMatthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory
Molecular Profiling Matthew Smolkin, MD HCLD Medical Director Molecular Pathology Diagnostic Laboratory Objectives Defining molecular profiling Technologies Why do we profile tumors? Current testing &
More informationThe mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge
The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly
More informationBasket Trials: Features, Examples, and Challenges
: Features, s, and Challenges Lindsay A. Renfro, Ph.D. Associate Professor of Research Division of Biostatistics University of Southern California ASA Biopharm / Regulatory / Industry Statistics Workshop
More informationSummary... 2 TRANSLATIONAL RESEARCH Tumour gene expression used to direct clinical decision-making for patients with advanced cancers...
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 TRANSLATIONAL RESEARCH... 3 Tumour gene expression used to direct clinical decision-making for patients with advanced
More informationRath, N., and Olson, M. (2016) Regulation of pancreatic cancer aggressiveness by stromal stiffening. Nature Medicine, 22(5), pp. 462-463. There may be differences between this version and the published
More informationDall istologia alla caratterizzazione biomolecolare
Il carcinoma ovarico: approccio multidisciplinare e prospettive terapeutiche Dall istologia alla caratterizzazione biomolecolare Anna Pesci Ospedale SC Don Calabria, Negrar anna.pesci@sacrocuore.it Ovarian
More informationThe use of diagnostic FFPE material in cancer epidemiology research
The use of diagnostic FFPE material in cancer epidemiology research Neil O Callaghan Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne www.pedigree.org.au Overview Who
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationPersonalised medicine: Past, present and future
Kathmandu, Bir Hospital visit, August 2018 Personalised medicine: Past, present and future Rodney J. Scott University of Newcastle, NSW, Australia & Hunter Area Pathology Service Current Medical Care Started
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationMolecular Pathology of Gastric Cancer
Molecular Pathology of Gastric Cancer Novel insights and possible future applications Fátima Carneiro i3s/ipatimup& Medical Faculty/ CHS João Porto, Portugal Outline 1. Major histological types of gastric
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationHarmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY
Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY A NEW GENE A DAY.WHILE YOU ARE ENJOYING MORNING COFFEE From cancer.gov GOALS FOR THE CME TODAY A brief
More informationIntroduction to Cancer Bioinformatics and cancer biology. Anthony Gitter Cancer Bioinformatics (BMI 826/CS 838) January 20, 2015
Introduction to Cancer Bioinformatics and cancer biology Anthony Gitter Cancer Bioinformatics (BMI 826/CS 838) January 20, 2015 Why cancer bioinformatics? Devastating disease, no cure on the horizon Major
More informationoncogenes-and- tumour-suppressor-genes)
Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: jjchuu@mail.stust.edu.tw Genetic Basis of Cancer Cancer-causing mutations Disease of aging
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationCancer genetics
Cancer genetics General information about tumorogenesis. Cancer induced by viruses. The role of somatic mutations in cancer production. Oncogenes and Tumor Suppressor Genes (TSG). Hereditary cancer. 1
More informationHuman Genetics 542 Winter 2018 Syllabus
Human Genetics 542 Winter 2018 Syllabus Monday, Wednesday, and Friday 9 10 a.m. 5915 Buhl Course Director: Tony Antonellis Jan 3 rd Wed Mapping disease genes I: inheritance patterns and linkage analysis
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More information7th Annual Symposium on Gastrointestinal Cancers " St. Louis, Mo, 9/20/08
Molecular markers to aid in early diagnosis of pancreatic cancer Michael Goggins, MD Professor of Pathology, Medicine and Oncology Johns Hopkins Medical Institutions, Baltimore, MD 7th Annual Symposium
More informationChromothripsis: A New Mechanism For Tumorigenesis? i Fellow s Conference Cheryl Carlson 6/10/2011
Chromothripsis: A New Mechanism For Tumorigenesis? i Fellow s Conference Cheryl Carlson 6/10/2011 Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development Cell 144,
More informationLESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2
For a complete list of defined terms, see the Glossary. Transformation the process by which a cell acquires characteristics of a tumor cell. LESSON 3.2 WORKBOOK How do normal cells become cancer cells?
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationThe Cancer Genome Atlas & International Cancer Genome Consortium
The Cancer Genome Atlas & International Cancer Genome Consortium Session 3 Dr Jason Wong Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 31 st July 2014 1
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationIntroduction to Cancer Biology
Introduction to Cancer Biology Robin Hesketh Multiple choice questions (choose the one correct answer from the five choices) Which ONE of the following is a tumour suppressor? a. AKT b. APC c. BCL2 d.
More informationSection D: The Molecular Biology of Cancer
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Section D: The Molecular Biology of Cancer 1. Cancer results from genetic changes that affect the cell cycle 2. Oncogene proteins and faulty
More informationActivation of cellular proto-oncogenes to oncogenes. How was active Ras identified?
Dominant Acting Oncogenes Eugene E. Marcantonio, M.D. Ph.D. Oncogenes are altered forms of normal cellular genes called proto-oncogenes that are involved in pathways regulating cell growth, differentiation,
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationAsingle inherited mutant gene may be enough to
396 Cancer Inheritance STEVEN A. FRANK Asingle inherited mutant gene may be enough to cause a very high cancer risk. Single-mutation cases have provided much insight into the genetic basis of carcinogenesis,
More informationDOWNLOAD OR READ : UNDERSTANDING LUNG CANCER PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : UNDERSTANDING LUNG CANCER PDF EBOOK EPUB MOBI Page 1 Page 2 understanding lung cancer understanding lung cancer pdf understanding lung cancer The two main types of lung cancer are non-small
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More information